Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inh...

    2026-01-14

    Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Cancer and Angiogenesis Research

    Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8) is a small-molecule, multi-target tyrosine kinase inhibitor (TKI) that selectively inhibits VEGFR2, PDGFRβ, and FGFR1, with IC50 values of 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively, in cellular assays (Chen & Feng, 2019). The compound demonstrates potent anti-angiogenic activity in vitro and in vivo, outperforming sunitinib, sorafenib, and nintedanib in standardized benchmarks. Pharmacokinetic studies reveal high oral bioavailability (up to 77% in dogs), high plasma protein binding (93% in humans), and the ability to cross the blood-brain barrier. Safety profiles show a high median lethal dose (LD50 1735.9 mg/kg, 14-day oral, rats), indicating mild systemic toxicity and no significant organ/genetic toxicity under research conditions. APExBIO supplies validated Anlotinib (hydrochloride) for research use, supporting reproducible mechanistic and translational studies (APExBIO product page).

    Biological Rationale

    Tumor angiogenesis is critical for cancer growth and metastasis. Targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) signaling disrupts new blood vessel formation. Multi-target tyrosine kinase inhibitors (TKIs) like Anlotinib hydrochloride are designed to simultaneously inhibit VEGFR2, PDGFRβ, and FGFR1, overcoming redundancy in pro-angiogenic signaling (Chen & Feng, 2019). This approach addresses the limitations of single-target agents, which often lead to compensatory pathway activation and eventual therapeutic resistance. Anlotinib’s broad selectivity profile enables robust inhibition of endothelial cell migration and capillary tube formation, essential steps in neovascularization. The compound's oral bioavailability and favorable distribution, including into tumor and brain tissue, further support its use in advanced cancer models. For detailed systems biology context, see this article, which Anlotinib-focused research extends by providing quantitative pharmacokinetic and selectivity data.

    Mechanism of Action of Anlotinib (hydrochloride)

    Anlotinib (hydrochloride) acts as a highly selective, orally bioavailable TKI. It inhibits the kinase activity of VEGFR2, PDGFRβ, and FGFR1, blocking downstream signaling cascades such as the ERK pathway. In endothelial cell assays, Anlotinib suppresses VEGF-, PDGF-BB-, and FGF-2-induced migration and tube formation in a concentration-dependent manner. The reported IC50 values are:

    • VEGFR2: 5.6 ± 1.2 nM
    • PDGFRβ: 8.7 ± 3.4 nM
    • FGFR1: 11.7 ± 4.1 nM

    Anlotinib also inhibits other kinases linked to angiogenesis and tumor progression, including VEGFR1/3, FGFR2–4, PDGFRα, c-Kit, and Met (Chen & Feng, 2019). Downstream, blockade of ERK phosphorylation leads to cell cycle arrest and reduced endothelial cell proliferation. The net result is effective inhibition of tumor vascularization and growth. For deeper mechanistic context, see this mechanistic review, which this article updates by integrating new IC50 and specificity data.

    Evidence & Benchmarks

    • Anlotinib (hydrochloride) at nanomolar concentrations inhibits VEGFR2, PDGFRβ, and FGFR1 kinase activity in vitro (Chen & Feng 2019, DOI).
    • In cellular assays (EA.hy 926 endothelial cells), Anlotinib blocks VEGF-, PDGF-BB-, and FGF-2-induced migration and capillary-like tube formation (Chen & Feng 2019, DOI).
    • Pharmacokinetic studies report oral bioavailability of 28–58% in rats and 41–77% in dogs; plasma protein binding is 93% in humans (Chen & Feng 2019, DOI).
    • Tissue distribution shows high accumulation in lung, liver, kidney, heart, and tumor tissue, with blood-brain barrier penetration (Chen & Feng 2019, DOI).
    • The median lethal dose (LD50) after 14-day oral administration in rats is 1735.9 mg/kg, indicating low acute systemic toxicity (Chen & Feng 2019, DOI).
    • In a clinical case, Anlotinib reduced metastatic lymph nodes in a patient with intra-abdominal desmoplastic small round cell tumor after four cycles, with manageable side effects (Chen & Feng 2019, DOI).
    • Compared to sunitinib, sorafenib, and nintedanib, Anlotinib demonstrates superior inhibition of endothelial cell migration and tube formation (Chen & Feng 2019, DOI).

    For comparative experimental protocols and troubleshooting, see this workflow guide, which this article extends by providing quantitative selectivity and toxicity benchmarks.

    Applications, Limits & Misconceptions

    Anlotinib (hydrochloride) is suitable for in vitro and in vivo studies on tumor angiogenesis inhibition, cancer cell migration, and multi-pathway signaling modulation. It is validated for use in endothelial cell models (e.g., EA.hy 926) and animal studies exploring tumor growth and metastasis. The compound’s pharmacokinetic profile supports use in systemic and brain tumor models. However, it is not intended for diagnostic or therapeutic use in humans, and effects in non-angiogenic disease contexts are unproven. For translational and systems-level strategies, see this systems biology review; this article updates with recent clinical and preclinical benchmarks.

    Common Pitfalls or Misconceptions

    • Anlotinib is not approved for diagnostic or medical use; it is strictly for research applications.
    • Single-target studies may underestimate compensatory angiogenic pathway activation; Anlotinib’s value lies in multi-pathway inhibition.
    • Interpretation of in vivo results requires attention to pharmacokinetics and tissue distribution, especially for brain or poorly vascularized tumors.
    • Off-target effects outside of angiogenesis-related kinases are not well characterized and may vary by cell type.
    • Comparisons with other TKIs must use standardized concentrations and assay conditions to avoid bias.

    Workflow Integration & Parameters

    For research use, Anlotinib (hydrochloride) is typically dissolved in DMSO for stock solutions and stored at -20°C. Working concentrations in cellular assays range from 1 nM to 1 μM, with effects on endothelial cell migration and tube formation observable at nanomolar levels. In animal models, dosing regimens should be based on published pharmacokinetics and tissue distribution data. The compound is metabolized primarily by CYP3A, producing hydroxylated and dealkylated metabolites, with minimal unchanged drug excreted. For advanced workflow integration, see this translational strategy guide, which this article clarifies by providing updated safety and distribution parameters.

    Researchers can obtain validated Anlotinib (hydrochloride) (SKU: C8688) directly from APExBIO, ensuring product consistency and reproducibility for anti-angiogenic and cancer signaling studies.

    Conclusion & Outlook

    Anlotinib hydrochloride represents a next-generation, multi-target TKI for research in tumor angiogenesis and cancer biology. Its superior selectivity, potency, and pharmacokinetic properties make it an essential tool for dissecting VEGFR2, PDGFRβ, and FGFR1 signaling pathways. Ongoing research will clarify its applications in additional tumor models and combination regimens. For robust results and reproducibility, sourcing through APExBIO is recommended. As the field advances, Anlotinib will continue to facilitate insights into complex angiogenic networks and support the development of new cancer research paradigms (Chen & Feng, 2019).